Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Non-Current Assets (2016 - 2025)

Integra Lifesciences Holdings (IART) has disclosed Non-Current Assets for 17 consecutive years, with $2.4 billion as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 17.37% to $2.4 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.4 billion through Dec 2025, down 9.79% year-over-year, with the annual reading at $2.4 billion for FY2025, 17.37% down from the prior year.
  • Non-Current Assets hit $2.4 billion in Q4 2025 for Integra Lifesciences Holdings, down from $2.5 billion in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $3.0 billion in Q3 2024 to a low of $2.4 billion in Q4 2025.
  • Historically, Non-Current Assets has averaged $2.7 billion across 5 years, with a median of $2.7 billion in 2021.
  • Biggest five-year swings in Non-Current Assets: increased 16.04% in 2021 and later decreased 17.37% in 2025.
  • Year by year, Non-Current Assets stood at $2.6 billion in 2021, then rose by 3.79% to $2.7 billion in 2022, then decreased by 0.16% to $2.7 billion in 2023, then grew by 8.51% to $3.0 billion in 2024, then fell by 17.37% to $2.4 billion in 2025.
  • Business Quant data shows Non-Current Assets for IART at $2.4 billion in Q4 2025, $2.5 billion in Q3 2025, and $2.5 billion in Q2 2025.